Drugs / ZVS203e
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT05805007 | Sep 2023 → Apr 2026 | retinitis pigmentosa | Peking University Third Hospital | Unknown | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT06952842 | Aug 2025 → Jun 2030 expected | retinitis pigmentosa | Chigenovo Co., Ltd | Recruiting | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ZVS203e | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06952842 ↗ |
| Action | Inhibit | “silences RHO mutant protein expression” NCT05805007 ↗ |
| Modality | CRISPR / gene editing | “CRISPR/Cas9 editing system” NCT05805007 ↗ |
| Route | Other | “subretinal injection” NCT05805007 ↗ |
| Target | RHO | “silences RHO mutant protein expression” NCT05805007 ↗ |